Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: September 2012

Is Novartis building a viable business model for adoptive immunotherapy for cancer?

Tweet  On April 27, 2011 we published an article on this blog entitled “Adoptive immunotherapy for metastatic melanoma?” This blog post, which was in part based on an article in the April 2011 issue of The Scientist, described a treatment for metastatic melanoma known as adoptive cell transfer (ACT), or adoptive immunotherapy. ACT is the…

Alzheimer’s disease–where do we go from here?

Tweet  Our August 19, 2012 and our August 28, 2012 articles on this blog focused on the latest developments in Alzheimer’s disease (AD) drug development. To summarize the conclusions of the articles: The results of a new genetic study by DeCode Genetics and its collaborators strongly support the amyloid hypothesis of AD, and especially the…